SPY421.97-0.14 -0.03%
DIA338.65-2.11 -0.62%
IXIC14,161.35+121.67 0.87%

Intra-Cellular Therapies Reports Narrower Q1 Loss, Revenue Higher

05/10/2021 04:34

08:19 AM EDT, 05/10/2021 (MT Newswires) -- Intra-Cellular Therapies (ITCI) on Monday reported a net loss of $0.65 per share in Q1 compared with a loss of $0.73 per share in the previous year. Analysts surveyed by Capital IQ were expecting a net loss of $0.80 per share.

Revenue amounted to $15.9 million, up from $1.1 million a year ago. Analysts were expecting revenue of $16.9 million.

Cash, cash equivalents, restricted cash and investment securities amounted to $613.4 million at the end of Q1, down from $658.8 million at the end of the prior quarter.

Price: 35.03, Change: +1.60, Percent Change: +4.79